Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer’s Disease

Enrica Cavedo 1 Bruno Dubois 2, 3 Olivier Colliot 3, 4, 5, 6 Simone Lista 2, 3 Bernard Croisile 7 Guy Louis Tisserand 8 Jacques Touchon 9 Alain Bonafe 10 Pierre J. Ousset 11 Olivier Rouaud 12 Fréderic Ricolfi 13 Alain Vighetto 14 Florence Pasquier 15, 16 Samantha Galluzzi 17 Christine Delmaire 18 Mathieu Ceccaldi 19 Nadine Girard 20 Stéphane Lehericy 2, 6 Françoise Duveau 21 Marie Chupin 4 Marie Sarazin 22 Didier Dormont 4, 23 Harald Hampel 3
Abstract : OBJECTIVE: Cortical thinning, previously identified during prodromal stages of Alzheimer's disease (AD), is a "candidate" biomarker implemented in AD clinical therapy trials. We investigated the effect of donepezil treatment on cortical thickness in mild cognitively impaired subjects with the amnestic syndrome of the hippocampal type, a prodromal at-risk group for progression to AD dementia. METHODS: Data were from a longitudinal analysis of a community-based multicenter suspected prodromal AD cohort diagnosed by the Free and Cued Selective Reminding Test (81 donepezil vs 92 placebo) enrolled in a double-blind, randomized, placebo-controlled parallel group design using donepezil (10 mg/day). The study started in November 2006 and concluded in August 2010. All subjects underwent 2 brain structural magnetic resonance imaging (MRI) scans, at baseline and at the end of the trial. Structural MRI images had been processed using the automated pipeline for longitudinal segmentation and surface reconstruction implemented in FreeSurfer. The primary outcome measure of this post hoc study was the annualized percentage change (APC) of cortical thickness. RESULTS: The donepezil group exhibited reduced APC cortical thinning compared to placebo in the rostral anterior cingulate (right: P = .048; left: P = .032), the orbitofrontal (right: P = .012; left: P < .048), and the right inferior frontal (P = .022) cortices and in the right insula (P = .010). These results were not statistically significant after Bonferroni correction likely due to insufficient power for cortical thickness measurements in the study group powered for the predefined hippocampus outcome. CONCLUSIONS: Our findings support the hypothesis that cortical thickness is a reliable candidate surrogate outcome in early predementia AD trials. In addition, donepezil treatment may have an impact on cortical structure/morphology in areas innervated by the medial and lateral cholinergic pathways.
Liste complète des métadonnées

Littérature citée [32 références]  Voir  Masquer  Télécharger

https://hal.inria.fr/hal-01388951
Contributeur : Olivier Colliot <>
Soumis le : samedi 12 novembre 2016 - 13:41:11
Dernière modification le : samedi 8 décembre 2018 - 01:22:57
Document(s) archivé(s) le : jeudi 16 mars 2017 - 11:36:04

Fichier

cavedo16_the Journal of Clinic...
Fichiers produits par l'(les) auteur(s)

Identifiants

Citation

Enrica Cavedo, Bruno Dubois, Olivier Colliot, Simone Lista, Bernard Croisile, et al.. Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer’s Disease. Journal of Clinical Psychiatry, Physicians Postgraduate Press, 2016, 〈10.4088/JCP.15m10413 〉. 〈hal-01388951〉

Partager

Métriques

Consultations de la notice

1096

Téléchargements de fichiers

376